Skip to main content
Monday, November 16, 2026Nov 16

US to resume J&J COVID vaccinations despite rare clot risk

In this March 26, 2021, file photo, a member of the Philadelphia Fire Department prepares a dose of the Johnson & Johnson COVID-19 vaccine at a vaccination site setup at a Salvation Army location in Philadelphia. With the U.S. pause of the vaccine, authorities are weighing whether to resume the shots the way European regulators decided to -- with warnings of a "very rare" risk. New guidance is expected late Friday, April 23, after a government advisory panel deliberates a link between the shot and a handful of vaccine recipients who developed highly unusual blood clots. (AP Photo/Matt Rourke, File)
In this March 26, 2021, file photo, a member of the Philadelphia Fire Department prepares a dose of the Johnson & Johnson COVID-19 vaccine at a vaccination site setup at a Salvation Army location in Philadelphia. With the U.S. pause of the vaccine, authorities are weighing whether to resume the shots the way European regulators decided to -- with warnings of a "very rare" risk. New guidance is expected late Friday, April 23, after a government advisory panel deliberates a link between the shot and a handful of vaccine recipients who developed highly unusual blood clots. (AP Photo/Matt Rourke, File)

U.S. health officials lifted an 11-day pause on COVID-19 vaccinations using Johnson & Johnson’s single-dose shot on Friday, after scientific advisers decided its benefits outweigh a rare risk of blood clot.

The government uncovered 15 vaccine recipients who developed a highly unusual kind of blood clot, out of nearly 8 million people given the J&J shot. All were women, most under age 50. Three died, and seven remain hospitalized.

But ultimately Friday, the Food and Drug Administration and Centers for Disease Control and Prevention decided that J&J’s one-and-done vaccine is critical to fight the pandemic – and that the small clot risk could be handled with warnings to help younger women decide if they should use that shot or an alternative.

“Above all else, health and safety are at the forefront of our decisions,” CDC Director Dr. Rochelle Walensky said in a statement. “Our vaccine safety systems are working. We identified exceptionally rare events – out of millions of doses” of the J&J shot and will continue to monitor them.

The U.S. decision – similar to how European regulators are rolling out J&J’s shot – comes after CDC advisers earlier Friday voted 10-4 to resume vaccinations but panelists made clear that they must come with warnings about the risk. The group debated but ultimately steered clear of outright age restrictions.